Knoll Pharmaceuticals Co. v. Teva Pharmaceuticals USA, Inc.

138 F. App'x 302
Court of Appeals for the Federal Circuit·Decided April 6, 2005·No. No. 05-1127·Published·Cited by 1 cases

Opinion

ON MOTION

MAYER, Circuit Judge.

ORDER

Teva Pharmaceuticals USA, Inc. moves to dismiss John D. Arnold, M.D.’s appeal because Arnold appeals from a nonfinal order and lacks standing. Arnold opposes and, in the alternative, petitions for a writ of mandamus. Teva replies.

Arnold is the inventor and licensed the rights to the patent at issue in this case to Knoll Pharmaceuticals Company, Inc. et al. The licensing agreement provided, in part, that “both parties agree to cooperate fully with each other” in any litigation challenging the patent’s validity. Knoll subsequently sued Teva in United States District Court for the Northern District of Illinois. During discovery, Teva moved to compel Knoll to produce 33 documents from Arnold’s files that Knoll claimed were protected by the attorney-client privilege. Although Arnold did not intervene in district court, he filed an opposition to Teva’s motion to compel. The district court concluded that the documents at issue were within the “custody and control” of Knoll based on the Knoll-Arnold licensing agreement and 30 of the documents were not [303]*303privileged. The district court ordered Knoll to produce those documents found to be nonprivileged.

Free access — add to your briefcase to read the full text and ask questions with AI

Knoll Pharmaceuticals Co. v. Teva Pharmaceuticals USA, Inc., 138 F. App'x 302 (Fed. Cir. 2005).

138 F. App'x 302 (Knoll Pharmaceuticals Co. v. Teva Pharmaceuticals USA, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Waymo LLC v. Uber Technologies, Inc.
870 F.3d 1350 (Federal Circuit, 2017)